Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D3.66 - National Survey on Perioperative Hypersensitivity Reactions: Clinical and Epidemiological Insights from Spanish Hospitals
D3.67 - Desensitization to Pertuzumab in a Patient with a Mixed Hipersensitivity Reaction
D3.69 - Tissue-Specific Allergen Distribution in Blue Swimmer Crab (Portunus pelagicus): Implications for Shellfish Allergy Diagnostics
D3.70 - Multiple Food Protein-Induced Enteropathy Syndrome: The Role of Skin Patch Testing in Guiding Effective Decision-Making
D3.71 - Anaphylaxis Induced by Macrogol: A Case Report
D3.72 - Utility of Basophil Activation Testing in Drug and Peanut Allergy: Concordance with Clinical Outcomes
D3.73 - Review of skin testing for delay hypersensitivity drug reactions, possible covariates involved in the results
D3.77 - Hypersensitivity Reactions to Iodinated Contrast Media: A Single-Center Experience
D3.78 - A rare case of scombroid syndrome with hypotension and biphasic course
D3.79 - Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata
D3.82 - Could Lipid Transfer Protein Induced Anaphylaxis Be a Surprising Outcome of Sleeve Gastrectomy?
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download